RxDoctor Payments Data

Federico Albrecht, MD

Hematology & Oncology · Miami, FLNPI 1366439689

Payments from drug & device makers

$123,345in general payments, 2019–2025

Across 213 payments — averaging $579.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$34K
  • Lilly USA, LLC$23K
  • Jazz Pharmaceuticals Inc.$15K
  • Gilead$13K
  • Merck$9K
  • E.r. Squibb & Sons, L.L.C.$9K
  • plus $20K from 20 others

What the payments were for

  • Consulting fees$22,00420%
  • Speaking & faculty fees$70,20364%
  • Travel & lodging$10,2169%
  • Food & beverage$7,1377%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,345 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$129,782
Medicare patients
266
Services billed
1,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate146$2,474,214
AlecensaAlectinib Hcl22$414,456
TabrectaCapmatinib Hydrochloride14$363,596
GilotrifAfatinib Dimaleate25$330,442
LorbrenaLorlatinib15$297,195
AlunbrigBrigatinib11$220,686
LumakrasSotorasib11$206,155
MekinistTrametinib Dimethyl Sulfoxide13$197,188
TafinlarDabrafenib Mesylate13$185,620
EliquisApixaban30$20,739
Erlotinib Hcl15$3,125
Megestrol Acetate31$3,024
Dexamethasone81$1,137
Lidocaine-PrilocaineLidocaine/Prilocaine83$1,036
Folic Acid108$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$745$2,474,214146 claims
Boehringer IngelheimGilotrif$34,018$330,44225 claims
Takeda Pharmaceuticals U.S.A., Inc.Alunbrig$125$220,68611 claims
AmgenLumakras$122$206,15511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →